Navigation Links
NxStage Announces Investor Conference Schedule

LAWRENCE, Mass., Aug. 6 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer and Robert Brown, Chief Financial Officer, will participate in the following schedule of investor conferences. Where possible, a webcast of each event will be made available at at the time of each conference.

Canaccord Adams Annual Global Growth Conference

Boston, MA

InterContinental Boston Hotel

Tuesday, August 12, 2008

9:00 a.m. EDT

Thomas Weisel Partners Healthcare Conference

Boston, MA

Four Seasons Hotel

Friday, September 5, 2008

8:35 a.m. EDT

UBS Global Life Sciences Conference

New York, NY

Grand Hyatt Hotel

Monday, September 22, 2008

Time to be determined.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Messrs. Burbank and Brown's plans to present at these conferences. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.


Kristen K. Sheppard, Esq.

Investor Relations

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
2. NxStage Medical to Present at William Blair Growth Stock Conference
3. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
4. NxStage Medical Announces Needle Supply Agreement with DaVita
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
7. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
8. NxStage Medical Provides Update on Medisystems Acquisition
9. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
10. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
11. China Pharma Holdings, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):